Surrozen, Inc. Common (SRZN) Stock Price

SRZNStock

$23.36+108.62%52W

Market Cap$274.56M

P/E—

PEG Ratio—

Div yield—

Beta0.53

SRZN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-15.71%

Price vs S&P 500 (4W)20.50%

VGM Score46.84

Book Value / Share (Quarterly)$5.50

P/TBV (Annual)0.14x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-34.72%

Cash Flow / Share (Quarterly)$-2.93

Price vs S&P 500 (YTD)-5.90%

Net Profit Margin (TTM)-4571.14%

EPS (TTM)$-35.44

10-Day Avg Trading Volume0.19M

EPS Excl Extra (TTM)$-35.44

EPS (Annual)$-32.37

ROI (Annual)-113.46%

Cash / Share (Quarterly)$9.30

Revenue Growth QoQ (YoY)408.65%

ROA (Last FY)-245.15%

Revenue Growth TTM (YoY)-35.61%

EBITD / Share (TTM)$-4.59

ROE (5Y Avg)-72.54%

Operating Margin (TTM)-573.75%

Cash Flow / Share (Annual)$-3.11

P/B Ratio5.92x

P/B Ratio (Quarterly)1.63x

Net Income / Employee (Annual)$-5,500,600

EV / Revenue (TTM)22.95x

Net Interest Coverage (TTM)-2.40x

ROA (TTM)-329.25%

EPS Incl Extra (Annual)$-32.37

Current Ratio (Annual)9.22x

Quick Ratio (Quarterly)11.70x

3-Month Avg Trading Volume0.17M

52-Week Price Return108.62%

Revenue / Employee (TTM)$170,300

Tangible BV / Share (Quarterly)$1.80

P/S Ratio (Annual)80.22x

Asset Turnover (Annual)0.04x

52-Week High$35.00

EPS Excl Extra (Annual)$-32.37

CapEx CAGR (5Y)-31.84%

26-Week Price Return-4.46%

Quick Ratio (Annual)9.01x

13-Week Price Return-11.52%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)11.91x

Enterprise Value$172.00M

Asset Turnover (TTM)0.07x

Revenue / Employee (Annual)$79,000

Pretax Margin (Annual)-6960.77%

Cash / Share (Annual)$9.13

3-Month Return Std Dev67.48%

Net Income / Employee (TTM)$-7,785,500

ROE (Last FY)-113.46%

EPS Basic Excl Extra (Annual)$-32.37

Receivables Turnover (TTM)1.96x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-35.44

Receivables Turnover (Annual)2.53x

ROI (TTM)58.23%

P/S Ratio (TTM)37.22x

Revenue / Share (Annual)$0.47

Tangible BV / Share (Annual)$2.53

Price vs S&P 500 (52W)90.31%

Year-to-Date Return6.06%

5-Day Price Return-0.13%

EPS Normalized (Annual)$-32.37

ROA (5Y Avg)-109.96%

Net Profit Margin (Annual)-6960.77%

Month-to-Date Return7.92%

Cash Flow / Share (TTM)$-1.11

EBITD / Share (Annual)$-5.56

Operating Margin (Annual)-1210.58%

ROI (5Y Avg)-72.54%

EPS Basic Excl Extra (TTM)$-35.44

P/TBV (Quarterly)0.20x

P/B Ratio (Annual)0.51x

Pretax Margin (TTM)-4571.14%

Book Value / Share (Annual)$18.39

Price vs S&P 500 (13W)-14.31%

Beta0.53x

Revenue / Share (TTM)$0.68

ROE (TTM)58.23%

52-Week Low$10.73

vGradeD

gGradeC

mGradeC

vgmGradeC

SRZN Earnings Surprise History

Q2 25-1.14est. -1.23

Q3 25-3.60est. -1.17

Q4 25-9.62est. -1.24

Q1 26-4.63est. -0.72

Q2 26-2.10est. -1.26

SRZN Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.18

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
SRZNSurrozen, Inc. Common	D	C	C	$23.36
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Surrozen, Inc. Common

Surrozen is a clinical-stage biotechnology company developing selective Wnt pathway modulators to promote tissue repair and regeneration across multiple organs. The company's pipeline includes three product candidates designed to address significant unmet medical needs in regenerative medicine. By targeting the Wnt signaling pathway, Surrozen aims to unlock the body's natural tissue repair mechanisms.